Amorphous crystal of tylonolide, and preparation method thereof

A new, amorphous technology of Tedirosan, applied in the preparation of sugar derivatives, chemical instruments and methods, sugar derivatives, etc., to achieve simple process steps, high purity, and reduce the effect of organic solvent residues
CN103554203AInactive Publication Date: 2014-02-05QILU ANIMAL HEALTH PROD
5 Cites 12 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
QILU ANIMAL HEALTH PROD
Publication Date
2014-02-05
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to an amorphous crystal of tylonolide, and a preparation method thereof. The TG-DSC spectrum of the amorphous crystal of tylonolide has an endothermic peak between 185DEG C and 210DEG C, and has an exothermic peak between 140DEG C and 175DEG C; and the XRPD atlas of the amorphous crystal of tylonolide contains no identifiable diffraction peak shapes. The invention also provides the preparation method of the amorphous crystal of tylonolide. The tylonolide having a new crystal form has the advantages of good dissolvability, good stability, good bioavailability, simple preparation, no need of a special apparatus, low production cost, and suitableness for the industrialized production.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to a new amorphous crystal of tediroate and a preparation method thereof, belonging to the technical field of preparation of veterinary antibiotics. Background technique

[0002] Tedirosin, molecular formula: C 41 h 71 N 3 o 8 Molecular weight: 734.02, chemical name: 20-deoxy-23-deoxy-5-oxo-[3,6-dideoxy-3-(dimethylamino)-β-D-glucopyranosyl]-20,23- Dipiperidinyl Tylenolide, whose structural formula (Formula I), is a broad-spectrum macrolide antibiotic developed by Intervet-Schering-Plough. In March 2011, the European Union (CVMP) approved the marketing of its injection. In veterinary medicine, it is mainly used for the treatment of bovine respiratory tract infection caused by Mannheimia haemolytica, Pasteurella multocida and Haemophilus somnus and by Actinobacillus pleuropneumoniae, Pasteurella multocida, bronchial sepsis wave Respiratory tract infection of pigs caused by Haemophilus parasuis and Haemophilus parasuis. [000...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More